

The CardioCare Platform Addresses Real-World Challenges in Structural Heart Disease Patient Care




The CardioCare platform uses big data analytics and artificial intelligence powered technology to help physicians elevate the standard of patient care.

Challenge #1: Reducing Mortality

Hospital systems face significant challenges that may unintentionally delay patient care. Poor outcomes and high mortality are possible costs of delayed therapy for untreated patients with severe structural heart disease (SHD). Hospital systems need a better way to identify their most at-risk patients.

The CardioCare platform applies Artificial Intelligence (AI) to millions of echos and uses proprietary predictive algorithms to help physicians identify patients who may have progressed from moderate to severe disease. The AI is applied on an individual patient level, as demonstrated in the predicted progression curve below.¹

Predicted Progression of Moderate Aortic Stenosis




¹Moualla, et al. JACC. 2021. <https://www.jacc.org/doi/10.1016/j.jacc.2021.09.908>. Graph depicts progression of one moderate aortic stenosis (AS) patient.



Challenge #2: Improving Guideline-Directed Therapy

Getting SHD patients on the right treatment plan is only half the battle when patients aren't referred to specialists for timely evaluation. Increasing appropriate referrals to the structural heart team is a step in the right direction for patient care and can help improve guideline-directed therapy.

Sites have observed the following guideline-directed procedural growth one year after implementing the CardioCare platform.²




²Analysis represents median growth from 8 CardioCare sites with baseline data one year after implementing the CardioCare program.

Challenge #3: Standardizing Quality

Minimizing variability in care is a critical part of improving patient outcomes, yet many cardiovascular programs have limited ability to understand where variation in care lies within their system. Real-world data from five heart programs managing 50,000 patients with heart failure and a reduced ejection fraction (HFrEF) indicate that despite evidence of improved outcomes, only 2.48% of patients with HFrEF are prescribed all four guideline-directed medications to treat HFrEF.³

The CardioCare platform provides actionable insights, helps physicians prioritize care for patients eligible for life-saving treatment, and standardizes quality of care across the entire structural heart patient population.

Low GDMT Prescription Rate for HFrEF Patients Despite Proven Benefits



³Early data representing 5 heart programs managing more than 50,000 HFrEF patients. HFrEF is defined as patients with heart failure and a reduced ejection fraction. Guideline Directed Medical Therapy (GDMT) is defined by patients being prescribed all 4 medications to treat HFrEF (1. ACEI/ARB/ARNI 2. Beta Blocker 3. MRA 4. SGLT2)

About egnite

egnite is a digital health company focused on providing artificial intelligence solutions to help hospitals identify and manage their most at-risk structural heart patients. The company is a market leader in structural heart solutions with a vision to improve the outcomes for every structural heart patient in America. egnite's flagship AI platform, CardioCare, has partnered with over 50 hospitals nationwide and leverages the program's big data analytics platform of over one million echos to elevate the standard of care for thousands of patients. The company is based in Aliso Viejo, California, for more information, visit egnitehealth.com.

Sparkling Transformation in Healthcare.

©2021 egnite, Inc. All Rights Reserved. egnite, egnite Inc., the spark logo, CardioCare, and the heart logo are trademarks of egnite, Inc or its affiliates. All other trademarks are property of their respective owners.

*The CardioCare Platform is not intended for use in the diagnosis, cure, mitigation, or prevention of structural heart diseases.

[Privacy Policy](#)

